HVTN 111: A Phase 1, HIV Preventive Vaccine Trial Opens at Matero Ref
AIDS, the disease caused by the human immunodeficiency virus (HIV) is a huge problem around the world, and especially in countries in sub-Saharan Africa such as Zambia. While we have an excellent ART treatment programme to help those infected with HIV/AIDS to live well, finding a safe and effective HIV vaccine that protects against getting the virus is key to ending the epidemic!
The HIV Vaccine Trials Network 111 is a Phase 1 clinical trial which is a carefully controlled and monitored research study which aims to find out if the specific study vaccine being used is safe and how the body’s defence mechanisms respond to it.
CIDRZ is the Zambian site conducting the HVTN 111 study. It is also being conducted at sites in South Africa and Tanzania. Funding for the study is provided by the HVTN, the US Division of AIDS (DAIDS), the Bill & Melinda Gates Foundation, GlaxoSmithKline (formerly Novartis) and the IPPOX Foundation.
About the HIV Vaccine Trials Network (www.hvtn.org)
The mission of the HVTN is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally. The HVTN, with expert scientists from medical institutions across the globe alongside top clinicians, educators, and dedicated community representatives, is committed to conducting scientifically rigorous and ethical trials.
All clinical studies done by the HVTN test the safety of vaccine candidates. They also look to see if people can get these vaccines without having side effects that make them very uncomfortable. They look at the immune responses that are generated in people who receive these vaccines. Some of their studies look at whether these vaccines protect against HIV infection, or control HIV if infection does occur (efficacy studies).
To date, the HVTN has conducted the majority of the published, presented, or ongoing clinical trials of preventive HIV vaccines worldwide. In the process, they have gained tremendous experience in administering an innovative global scientific organization, which combines the intellectual robustness and creativity of academia with the focus and infrastructure of industry.
CIDRZ is proud to partner with the HVTN in this important HIV research.